1. Home
  2. NGNE vs WNC Comparison

NGNE vs WNC Comparison

Compare NGNE & WNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$20.71

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

WNC

Wabash National Corporation

HOLD

Current Price

$8.39

Market Cap

392.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
WNC
Founded
2003
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Construction/Ag Equipment/Trucks
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
392.2M
IPO Year
2014
2009

Fundamental Metrics

Financial Performance
Metric
NGNE
WNC
Price
$20.71
$8.39
Analyst Decision
Strong Buy
Hold
Analyst Count
8
1
Target Price
$60.13
$11.00
AVG Volume (30 Days)
128.0K
446.1K
Earning Date
05-08-2026
04-29-2026
Dividend Yield
N/A
3.73%
EPS Growth
0.93
179.22
EPS
N/A
5.07
Revenue
N/A
$2,027,489,000.00
Revenue This Year
N/A
$0.53
Revenue Next Year
N/A
$25.53
P/E Ratio
N/A
$1.69
Revenue Growth
N/A
8.81
52 Week Low
$6.88
$6.78
52 Week High
$37.27
$12.94

Technical Indicators

Market Signals
Indicator
NGNE
WNC
Relative Strength Index (RSI) 48.94 40.08
Support Level $19.27 $8.07
Resistance Level $21.03 $9.33
Average True Range (ATR) 1.71 0.40
MACD -0.12 0.08
Stochastic Oscillator 39.84 45.97

Price Performance

Historical Comparison
NGNE
WNC

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About WNC Wabash National Corporation

Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.

Share on Social Networks: